Systematic review with meta-analysis: Coffee consumption and the risk of cirrhosis

Alimentary Pharmacology and Therapeutics

Volumn 43, Issue 5, 2016, Pages 562-574

  Kennedy, O J ^a   Roderick, P ^a   Buchanan, R ^a   Fallowfield, J A ^b   Hayes, P C ^b   Parkes, J ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COFFEE; DISEASE ASSOCIATION; FOOD INTAKE; HUMAN; LIVER CIRRHOSIS; MORTALITY; PRIORITY JOURNAL; RISK REDUCTION; SYSTEMATIC REVIEW; ADVERSE EFFECTS; ALCOHOL LIVER CIRRHOSIS; CASE CONTROL STUDY; CHEMICALLY INDUCED; CLINICAL TRIAL; COHORT ANALYSIS; DOSE RESPONSE; MULTICENTER STUDY; RISK; RISK ASSESSMENT;

COFFEE;

CASE-CONTROL STUDIES; COFFEE; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LIVER CIRRHOSIS; LIVER CIRRHOSIS, ALCOHOLIC; RISK; RISK ASSESSMENT;

EID: 84956626255     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13523     Document Type: Article

References (73)

1. Mokdad A, Lopez A, Shahraz S, et al,. Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. BMC Med 2014; 12: 145.
2. Bellentani S, Scaglioni F, Marino M, Bedogni G,. Epidemiology of non-alcoholic fatty liver disease. Dig Dis 2010; 28: 155-61.
3. Liu B, Balkwill A, Reeves G, Beral V,. Body mass index and risk of liver cirrhosis in middle aged UK women: prospective study. BMJ 2010; 340: c912.
4. Ludwig IA, Clifford MN, Lean ME, Ashihara H, Crozier A,. Coffee: biochemistry and potential impact on health. Food Funct 2014; 5: 1695-717.
5. Higdon JV, Frei B,. Coffee and health: a review of recent human research. Crit Rev Food Sci Nutr 2006; 46: 101-23.
6. Freedman ND, Everhart JE, Lindsay KL, et al,. Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology 2009; 50: 1360-9.
7. Corrao G, Zambon A, Bagnardi V, D'Amicis A, Klatsky A,. Coffee, caffeine, and the risk of liver cirrhosis. Ann Epidemiol 2001; 11: 458-65.
8. Setiawan VW, Wilkens LR, Lu SC, Hernandez BY, Le Marchand L, Henderson BE,. Association of coffee intake with reduced incidence of liver cancer and death from chronic liver disease in the US multiethnic cohort. Gastroenterology 2015; 148: 118-25; quiz e15.
9. Klatsky AL, Morton C, Udaltsova N, Friedman GD,. Coffee, cirrhosis, and transaminase enzymes. Arch Intern Med 2006; 166: 1190-5.
10. Bravi F, Bosetti C, Tavani A, Gallus S, La VC,. Coffee reduces risk for hepatocellular carcinoma: an updated meta-analysis. Clinical Gastroenterology and Hepatology 2013; 11: 1413-21.e1
11. Cardin R, Piciocchi M, Martines D, Scribano L, Petracco M, Farinati F,. Effects of coffee consumption in chronic hepatitis C: a randomized controlled trial. Dig Liver Dis 2013; 45: 499-504.
12. Tverdal A, Skurtveit S,. Coffee intake and mortality from liver cirrhosis. Ann Epidemiol 2003; 13: 419-23.
13. Lai GY, Weinstein SJ, Albanes D, et al,. The association of coffee intake with liver cancer incidence and chronic liver disease mortality in male smokers. Br J Cancer 2013; 109: 1344-51.
14. Goh GBB, Chow WC, Wang RW, Yuan JM, Koh WP,. Coffee, alcohol and other beverages in relation to cirrhosis mortality: the Singapore Chinese health study. Hepatology 2014; 60: 661-9.
15. Sterne J, Higgins J, Reeves B, ACROBAT-NRSI. obotdgf. A Cochrane risk of bias assessment tool: for non-randomized studies of interventions (ACROBAT-NRSI), Version 1.0.0, 24 September 2014. Available at: http://www.riskofbias.info (accessed 4 August 2015).
16. Imamura F, O'Connor L, Ye Z, et al,. Consumption of sugar sweetened beverages, artificially sweetened beverages, and fruit juice and incidence of type 2 diabetes: systematic review, meta-analysis, and estimation of population attributable fraction. BMJ 2015; 351: h3576.
17. Schünemann H, Brozek J, Oxman G,. Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach, 2013. Available at: www.guidelinedevelopment.org/handbook/ (accessed 4th August 2015).
18. Hamling J, Lee P, Weitkunat R, Ambuhl M,. Facilitating meta-analyses by deriving relative effect and precision estimates for alternative comparisons from a set of estimates presented by exposure level or disease category. Stat Med 2008; 27: 954-70.
19. Xie Y, Qin J, Nan G, Huang S, Wang Z, Su Y,. Coffee consumption and the risk of lung cancer: an updated meta-analysis of epidemiological studies. Eur J Clin Nutr 2015; doi: 10.1038/ejcn.2015.96 [Epub ahead of print].
20. Il'yasova D, Hertz-Picciotto I, Peters U, Berlin J, Poole C,. Choice of exposure scores for categorical regression in meta-analysis: a case study of a common problem. Cancer Causes Control 2005; 16: 383-8.
21. Greenland S, Longnecker MP,. Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am J Epidemiol 1992; 135: 1301-9.
22. Orsini N, Li R, Wolk A, Khudyakov P, Spiegelman D,. Meta-analysis for linear and nonlinear dose-response relations: examples, an evaluation of approximations, and software. Am J Epidemiol 2012; 175: 66-73.
23. Harris R, Bradburn M, Deeks J, Harbord R, Altman D, Sterne J,. Metan: fixed- and random-effects meta-analysis. Stata J 2008; 8: 3-28.
24. Higgins JPT, Green S, (eds) Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available at: www.cochrane-handbook.org (accessed 17 November 2015)
25. Greenland S,. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev 1987; 9: 1-30.
26. Macaskill P, Walter SD, Irwig L,. A comparison of methods to detect publication bias in meta-analysis. Stat Med 2001; 20: 641-54.
27. Stucker I, N'Kontchou G, Loriot MA, et al,. Does coffee drinking protect cirrhotic patients against hepatocellular carcinoma? Hepatology 2006; 44: 501A-A.
28. Corrao G, Lepore AR, Torchio P, et al,. The effect of drinking coffee and smoking cigarettes on the risk of cirrhosis associated with alcohol consumption. Eur J Epidemiol 1994; 10: 657-64.
29. Gallus S, Tavani A, Negri E, La Vecchia C,. Does coffee protect against liver cirrhosis? Ann Epidemiol 2002; 12: 202-5.
30. Larsson SC, Wolk A,. Coffee consumption and risk of liver cancer: a meta-analysis. Gastroenterology 2007; 132: 1740-5.
31. Sang LX, Chang B, Li XH, Jiang M,. Consumption of coffee associated with reduced risk of liver cancer: a meta-analysis. BMC Gastroenterol 2013; 13: 13-34.
32. Homan DJ, Mobarhan S,. Coffee: good, bad, or just fun? A critical review of coffee's effects on liver enzymes. Nutr Rev 2006; 64: 43-6.
33. Poyrazoglu OK, Bahcecioglu IH, Ataseven H, et al,. Effect of unfiltered coffee on carbon tetrachloride-induced liver injury in rats. Inflammation 2008; 31: 408-13.
34. Ruhl CE, Everhart JE,. Coffee and tea consumption are associated with a lower incidence of chronic liver disease in the United States. Gastroenterology 2005; 129: 1928-36.
35. Walton HB, Masterton GS, Hayes PC,. An epidemiological study of the association of coffee with chronic liver disease. Scott Med J 2013; 58: 217-22.
36. Triantos C, Manolakopoulos S, Smirnidis A, et al,. Is caffeine responsible for the hepatoprotective effect of coffee consumption in patients with chronic liver diseases? A multicentre study. Gastroenterology 2013; 1: S1008.
37. Stroffolini T, Cotticelli G, Medda E, et al,. Interaction of alcohol intake and cofactors on the risk of cirrhosis. Liver Int 2010; 30: 867-70.
38. Hasegawa M, Yamada S, Hirayama C,. Fasting plasma caffeine level in cirrhotic patients: relation to plasma levels of catecholamines and renin activity. Hepatology 1989; 10: 973-7.
39. Rodopoulos N, Wisen O, Norman A,. Caffeine metabolism in patients with chronic liver disease. Scand J Clin Lab Invest 1995; 55: 229-42.
40. Morrison A, Polisena J, Husereau D, et al,. The effect of English-language restriction on systematic review-based meta-analyses: a systematic review of empirical studies. Int J Technol Assess Health Care 2012; 28: 138-44.
41. Juni P, Holenstein F, Sterne J, Bartlett C, Egger M,. Direction and impact of language bias in meta-analyses of controlled trials: empirical study. Int J Epidemiol 2002; 31: 115-23.
42. Dickersin K, Chan S, Chalmersx TC, Sacks HS, Smith Jr H,. Publication bias and clinical trials. Control Clin Trials 1987; 8: 343-53.
43. Arauz J, Galicia-Moreno M, Cortes-Reynosa P, Salazar EP, Muriel P,. Coffee attenuates fibrosis by decreasing the expression of TGF-beta and CTGF in a murine model of liver damage. J Appl Toxicol 2013; 33: 970-9.
44. Feld JJ, Lavoie EG, Michel F, Dranoff JA,. I drink for my liver, Doc: emerging evidence that coffee prevents cirrhosis. F1000Research 2015; 4: 95.
45. Roderfeld M, Hemmann S, Roeb E,. Mechanisms of fibrinolysis in chronic liver injury (with special emphasis on MMPs and TIMPs). Z Gastroenterol 2007; 45: 25-33.
46. Che J, Chan ES, Cronstein BN,. Adenosine A2A receptor occupancy stimulates collagen expression by hepatic stellate cells via pathways involving protein kinase A, Src, and extracellular signal-regulated kinases 1/2 signaling cascade or p38 mitogen-activated protein kinase signaling pathway. Mol Pharmacol 2007; 72: 1626-36.
47. Chan ESL, Montesinos MC, Fernandez P, et al,. Adenosine A(2A) receptors play a role in the pathogenesis of hepatic cirrhosis. Br J Pharmacol 2006; 148: 1144-55.
48. Lv X, Chen Z, Li J, et al,. Caffeine protects against alcoholic liver injury by attenuating inflammatory response and oxidative stress. Inflamm Res 2010; 59: 635-45.
49. Xiao Q, Sinha R, Graubard BI, Freedman ND,. Inverse associations of total and decaffeinated coffee with liver enzyme levels in National Health and Nutrition Examination Survey 1999-2010. Hepatology 2014; 60: 2091-8.
50. Batista MN, Carneiro BM, Braga AC, Rahal P,. Caffeine inhibits hepatitis C virus replication in vitro. Arch Virol 2015; 160: 399-407.
51. Tanida I, Shirasago Y, Suzuki R, et al,. Inhibitory effects of caffeic acid, a coffee-related organic acid, on the propagation of hepatitis C virus. Jpn J Infect Dis 2015; 68: 268-75.
52. Wang GF, Shi LP, Ren YD, et al,. Anti-hepatitis B virus activity of chlorogenic acid, quinic acid and caffeic acid in vivo and in vitro. Antiviral Res 2009; 83: 186-90.
53. Ding M, Bhupathiraju SN, Chen M, van Dam RM, Hu FB,. Caffeinated and decaffeinated coffee consumption and risk of type 2 diabetes: a systematic review and a dose-response meta-analysis. Diabetes Care 2014; 37: 569-86.
54. Thong FSL, Graham TE,. Caffeine-induced impairment of glucose tolerance is abolished by β-adrenergic receptor blockade in humans. J Appl Physiol 2002; 92: 2347-52.
55. van Dam RM, Willett WC, Manson JE, Hu FB,. Coffee, caffeine, and risk of type 2 diabetes: a prospective cohort study in younger and middle-aged U.S. women. Diabetes Care 2006; 29: 398-403.
56. Bhupathiraju SN, Pan A, Malik VS, et al,. Caffeinated and caffeine-free beverages and risk of type 2 diabetes. Am J Clin Nutr 2013; 97: 155-66.
57. Herling AW, Burger HJ, Schwab D, Hemmerle H, Below P, Schubert G,. Pharmacodynamic profile of a novel inhibitor of the hepatic glucose-6-phosphatase system. Am J Physiol 1998; 274: G1087-93.
58. Greenberg JA, Boozer CN, Geliebter A,. Coffee, diabetes, and weight control. Am J Clin Nutr 2006; 84: 682-93.
59. van Dijk AE, Olthof MR, Meeuse JC, Seebus E, Heine RJ, van Dam RM,. Acute effects of decaffeinated coffee and the major coffee components chlorogenic acid and trigonelline on glucose tolerance. Diabetes Care 2009; 32: 1023-5.
60. van Dam RM,. Coffee and type 2 diabetes: from beans to beta-cells. Nutr Metab Cardiovasc Dis 2006; 16: 69-77.
61. Lopez-Ridaura R, Willett WC, Rimm EB, et al,. Magnesium intake and risk of type 2 diabetes in men and women. Diabetes Care 2004; 27: 134-40.
62. Okano J, Nagahara T, Matsumoto K, Murawaki Y,. Caffeine inhibits the proliferation of liver cancer cells and activates the MEK/ERK/EGFR signalling pathway. Basic Clin Pharmacol Toxicol 2008; 102: 543-51.
63. Cavin C, Holzhaeuser D, Scharf G, Constable A, Huber WW, Schilter B,. Cafestol and kahweol, two coffee specific diterpenes with anticarcinogenic activity. Food Chem Toxicol 2002; 40: 1155-63.
64. Huber WW, Scharf G, Rossmanith W, et al,. The coffee components kahweol and cafestol induce gamma-glutamylcysteine synthetase, the rate limiting enzyme of chemoprotective glutathione synthesis, in several organs of the rat. Arch Toxicol 2002; 75: 685-94.
65. Bamia C, Lagiou P, Jenab M, et al,. Coffee, tea and decaffeinated coffee in relation to hepatocellular carcinoma in a European population: multicentre, prospective cohort study. Int J Cancer J Int Cancer 2015; 136: 1899-908.
66. Yin X, Yang J, Li T, et al,. The effect of green tea intake on risk of liver disease: a meta analysis. Int J Clin Exp Med 2015; 8: 8339-46.
67. Wu W, Tong Y, Zhao Q, Yu G, Wei X, Lu Q,. Coffee consumption and bladder cancer: a meta-analysis of observational studies. Sci Rep 2015; 5: 9051.
68. Liu H, Yao K, Zhang W, Zhou J, Wu T, He C,. Coffee consumption and risk of fractures: a meta-analysis. Arch Med Sci 2012; 8: 776-83.
69. Freedman ND, Park Y, Abnet CC, Hollenbeck AR, Sinha R,. Association of coffee drinking with total and cause-specific mortality. N Engl J Med 2012; 366: 1891-904.
70. Qi H, Li S,. Dose-response meta-analysis on coffee, tea and caffeine consumption with risk of Parkinson's disease. Geriatr Gerontol Int 2014; 14: 430-9.
71. Nkondjock A,. Coffee consumption and the risk of cancer: an overview. Cancer Lett 2009; 277: 121-5.
72. Kokubo Y, Iso H, Saito I, et al,. The impact of green tea and coffee consumption on the reduced risk of stroke incidence in Japanese population: the Japan public health center-based study cohort. Stroke 2013; 44: 1369-74.
73. Taylor F, Huffman MD, Macedo AF, et al,. Statins for the primary prevention of cardiovascular disease. The Cochrane database of systematic reviews. 2013; 1: CD004816.